Compare Campbell Soup Co. (CPB) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Nuwellis Inc — how do they compare? Campbell Soup Co. trades at $19.38 (market cap $5.64B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Campbell Soup Co. is far larger — about 2563.6× Nuwellis Inc's market cap, and Campbell Soup Co. pays a 5.29% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Nuwellis Inc for 26 Days on average.
| CPB | NUWE | |
|---|---|---|
Market Cap | $5.64B | $2.20M |
Volume | 8,200,811 | 121,544 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $146.65 |
52-Week Low | $18.90 | $0.68 |
Typical Hold Time | 98 Days | 26 Days |
Enterprise Value | $12.70B | -$1.52M |
Dividend Yield | 5.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $19.37, up 1.95% on the day, with a bearish technical outlook and mixed fundamentals. Recent Q4 2026 earnings missed expectations, while the company implemented a 36% dividend cut and announced a $500 million cost-savings plan. Valuation metrics appear reasonable with P/E of 14.44 and P/S of 0.58, but profit margins have declined from 9.16% in 2023 to 4.13% projected for 2026.
The outlook remains challenging with declining profitability and bearish analyst sentiment, though current valuation may offer value for patient investors. Key risks include ongoing margin pressure, competitive threats, and execution of the turnaround plan. With only 6.9% of analysts rating it Buy, the stock faces significant headwinds despite trading near consensus price target of $19.67.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
